ClinicalTrials.gg
CompletedNCT04767646BLOCALGOUpdated Jun 3, 2026

Evaluation of the Relationship Between the Duration of the Evolution of the Complex Regional Pain Syndrome Type 1 (CRPS 1) and Effectiveness of the Continuous Peripheral Nerve Block (CPNB) Associated With an Intensive Rehabilitation Program

An interventional study of Intensive rehabilitation program with CPNB in CRPS (Complex Regional Pain Syndrome) Type I, sponsored by Pôle Saint Hélier. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Complex Regional Pain Syndromes with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Complex Regional Pain Syndromes · France.

Enrollment
10th of 13
30 · median 60
Started
2021
with 4 others
No phase
10 of 17
4 open now
Registered
9th of 17
by date

Among the 17 studies in Complex Regional Pain Syndromes with a site in France, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2021, is one of 10 with no phase, and was the 9th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

6 of the 17 studies in Complex Regional Pain Syndromes with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Complex Regional Pain Syndromes with a site in France, or all of them as a file.
02

Study summary

The study evaluates the relationship between the duration of evolution of SDRC1 and the efficacy of continuous peripheral nerve block (c-PNB) associated with an intensive rehabilitation program to improve the therapeutic strategy of SDRC1.

The main hypothesis of this study is that if c-PNB is proposed earlier, the recovery, measured with a scale achievement of objectives, will be better.

03

Conditions studied

  • CRPS (Complex Regional Pain Syndrome) Type I
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed
  • Diagnosis of CRPS type 1 according to BUDAPEST criteria to the upper or lower limb
  • Affiliated to a social security scheme (beneficiary or entitled person)
  • Patients justifying the installation of a Continuous Peripheral Nerve Block (CPNB) including pain rebellious to physical and medicinal treatments, the presence of fixed dystonia, or kinesiphobia or who are no longer progressing in the rehabilitation algorithm and requiring the need for a specialised technical platform.

Exclusion criteria

Exclusion Criteria:

  • CRPS Type 2
  • to the analgesics used (bupivacaine, ropivacaine, levobupivacaine)
  • Severe psychiatric decompensation
  • Under legal protection measures
  • Pregnant women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    C-BNP with intensive rehabilitation program

    Procedure: Intensive rehabilitation program with CPNB

Interventions

  • ProcedureIntensive rehabilitation program with CPNB

    The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB. The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program

06

What researchers measure

Primary outcomes

  1. The composite score (the summation of the 3 Goal Attainment Scaling (GAS) scores)

    The improvement of the composite score following BNPc combined with intensive rehabilitation.

    Time frame: 1 year

Secondary outcomes

  1. Pain assessment

    EVA (Visual Analogue Scale, VAS) for all the patients at each visit This is a measure of pain intensity on a scale of 0 (no pain) to 10 (very severe pain). We will assess the percentage of pain relief with the EVA scale, before and after the PCNB.

    Time frame: 1 year

  2. Anxiety assessment

    Hospital Anxiety and Depression (HAD) scale for all the patients at each visit There will be 2 scores One to assess anxiety : from 0 to 21 and one to assess depression : from 0 to 21 Higher scores mean a worse outcome.

    Time frame: 1 year

  3. Arthrometry assessment

    For an upper limb block : Passive and active arthrometry (angular measurements for shoulder, elbow and wrist) For a block of the lower limb : Passive and active arthrometry (angular measurements for hip, knee and ankle)

    Time frame: 1 year

  4. hand joint assessment

    For an upper limb block : Kapandji Index at each visit (between 0 to 10)

    Time frame: 1 year

  5. gripping force assessment

    For an upper limb block, gripping force will be evaluated with a Jamar and Pinch dynamometer at each visit after BNPc

    Time frame: 1 year

  6. activity assessment

    For an upper limb block, the activity limitation will be evaluated by leroux's scapular index (LSI) with a global score out of 100 at each visit after BNPc

    Time frame: 1 year

  7. manual dexterity test

    For an upper limb block, the dexterity will be evaluated by a Box and Block Test at each visit after BNPc

    Time frame: 1 year

  8. Assessment of activity limitation for a block of the upper limb

    DASH scale at each visit

    Time frame: 1 year

  9. Assessment of activity limitation for a block of the lower limb

    WOMAC score at each visit

    Time frame: 1 year

  10. Assessment of functional capacity

    TDM6 at each visit (number of metres travelled by the patient during 6 minutes)

    Time frame: 1 year

  11. Assessment of the restriction of participation in social life

    Return to work

    Time frame: 1 year

  12. Evaluation of the effective dose

    \- Recording of effective doses (continuous and bolus)

    Time frame: During the CPNB

  13. Evaluation of the tolerance of CPNB

    \- Incident reporting

    Time frame: During the CPNB

07

Study locations

1 site
  • Pôle Saint Hélier
    Rennes, Brittany Region 35000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2026, 60 months.

Of 66 non-industry interventional studies with no phase under Complex Regional Pain Syndromes, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's 60 months is above that.

Counting every sponsor, half of 67 studies reached it within 24 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 23, 2021
StartActual
Feb 23, 2021
Primary completionActual
Mar 10, 2026
CompletionActual
Mar 10, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04767646
Lead sponsor
Pôle Saint Hélier
Responsible party
Sponsor
First posted
Feb 23, 2021
Start date
Feb 23, 2021
Primary completion
Mar 10, 2026
Completion
Mar 10, 2026
Last update
Jun 3, 2026

Study contacts

Philippe Gallien, Doctor
principal investigator · Pôle Saint Hélier

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion